Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

Melania Carlisi, Franco Aversa, Marianna Criscuolo, Nicola Polverelli, Francesca Farina, Gianpaolo Nadali, Silvia Pascale, Lucia Prezioso, Anna Pegoraro, Maria Chiara Tisi, Federica Lessi, Roberta Di Blasi, Angelica Spolzino, Laura Maracci, Alessandro Busca, Anna Candoni, Benedetta Rambaldi, Mario Tumbarello, Angelica Barone, Gloria TurriAngela Passi, Mitja Nabergoj, Benedetta Cambò, Barbara Beggia, Angela Maria Quinto, Livio Pagano, Marco Sanna, Maria Ilaria Del Principe, Francesco Marchesi, Rosa Fanci, Leonardo Potenza, Annamaria Nosari, Chiara Cattaneo, Simone Cesaro, Domenico Russo

Risultato della ricerca: Article

36 Citazioni (Scopus)

Abstract

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.
Lingua originaleEnglish
pagine (da-a)17-29
Numero di pagine13
RivistaBlood Reviews
Volume31
Stato di pubblicazionePublished - 2017

Fingerprint

Hematologic Neoplasms
Candidemia
Mortality
Mycoses
Hematopoietic Stem Cell Transplantation
Fusarium
Immunocompromised Host
Aspergillus
Neutropenia
Causality
Fungi
Yeasts
Invasive Fungal Infections
Morbidity
Drug Therapy
Infection

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

Carlisi, M., Aversa, F., Criscuolo, M., Polverelli, N., Farina, F., Nadali, G., ... Russo, D. (2017). Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews, 31, 17-29.

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. / Carlisi, Melania; Aversa, Franco; Criscuolo, Marianna; Polverelli, Nicola; Farina, Francesca; Nadali, Gianpaolo; Pascale, Silvia; Prezioso, Lucia; Pegoraro, Anna; Tisi, Maria Chiara; Lessi, Federica; Di Blasi, Roberta; Spolzino, Angelica; Maracci, Laura; Busca, Alessandro; Candoni, Anna; Rambaldi, Benedetta; Tumbarello, Mario; Barone, Angelica; Turri, Gloria; Passi, Angela; Nabergoj, Mitja; Cambò, Benedetta; Beggia, Barbara; Quinto, Angela Maria; Pagano, Livio; Sanna, Marco; Del Principe, Maria Ilaria; Marchesi, Francesco; Fanci, Rosa; Potenza, Leonardo; Nosari, Annamaria; Cattaneo, Chiara; Cesaro, Simone; Russo, Domenico.

In: Blood Reviews, Vol. 31, 2017, pag. 17-29.

Risultato della ricerca: Article

Carlisi, M, Aversa, F, Criscuolo, M, Polverelli, N, Farina, F, Nadali, G, Pascale, S, Prezioso, L, Pegoraro, A, Tisi, MC, Lessi, F, Di Blasi, R, Spolzino, A, Maracci, L, Busca, A, Candoni, A, Rambaldi, B, Tumbarello, M, Barone, A, Turri, G, Passi, A, Nabergoj, M, Cambò, B, Beggia, B, Quinto, AM, Pagano, L, Sanna, M, Del Principe, MI, Marchesi, F, Fanci, R, Potenza, L, Nosari, A, Cattaneo, C, Cesaro, S & Russo, D 2017, 'Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations', Blood Reviews, vol. 31, pagg. 17-29.
Carlisi, Melania ; Aversa, Franco ; Criscuolo, Marianna ; Polverelli, Nicola ; Farina, Francesca ; Nadali, Gianpaolo ; Pascale, Silvia ; Prezioso, Lucia ; Pegoraro, Anna ; Tisi, Maria Chiara ; Lessi, Federica ; Di Blasi, Roberta ; Spolzino, Angelica ; Maracci, Laura ; Busca, Alessandro ; Candoni, Anna ; Rambaldi, Benedetta ; Tumbarello, Mario ; Barone, Angelica ; Turri, Gloria ; Passi, Angela ; Nabergoj, Mitja ; Cambò, Benedetta ; Beggia, Barbara ; Quinto, Angela Maria ; Pagano, Livio ; Sanna, Marco ; Del Principe, Maria Ilaria ; Marchesi, Francesco ; Fanci, Rosa ; Potenza, Leonardo ; Nosari, Annamaria ; Cattaneo, Chiara ; Cesaro, Simone ; Russo, Domenico. / Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. In: Blood Reviews. 2017 ; Vol. 31. pagg. 17-29.
@article{89848d9b11f4473e9258be10d647f7d6,
title = "Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations",
abstract = "Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.",
author = "Melania Carlisi and Franco Aversa and Marianna Criscuolo and Nicola Polverelli and Francesca Farina and Gianpaolo Nadali and Silvia Pascale and Lucia Prezioso and Anna Pegoraro and Tisi, {Maria Chiara} and Federica Lessi and {Di Blasi}, Roberta and Angelica Spolzino and Laura Maracci and Alessandro Busca and Anna Candoni and Benedetta Rambaldi and Mario Tumbarello and Angelica Barone and Gloria Turri and Angela Passi and Mitja Nabergoj and Benedetta Camb{\`o} and Barbara Beggia and Quinto, {Angela Maria} and Livio Pagano and Marco Sanna and {Del Principe}, {Maria Ilaria} and Francesco Marchesi and Rosa Fanci and Leonardo Potenza and Annamaria Nosari and Chiara Cattaneo and Simone Cesaro and Domenico Russo",
year = "2017",
language = "English",
volume = "31",
pages = "17--29",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

AU - Carlisi, Melania

AU - Aversa, Franco

AU - Criscuolo, Marianna

AU - Polverelli, Nicola

AU - Farina, Francesca

AU - Nadali, Gianpaolo

AU - Pascale, Silvia

AU - Prezioso, Lucia

AU - Pegoraro, Anna

AU - Tisi, Maria Chiara

AU - Lessi, Federica

AU - Di Blasi, Roberta

AU - Spolzino, Angelica

AU - Maracci, Laura

AU - Busca, Alessandro

AU - Candoni, Anna

AU - Rambaldi, Benedetta

AU - Tumbarello, Mario

AU - Barone, Angelica

AU - Turri, Gloria

AU - Passi, Angela

AU - Nabergoj, Mitja

AU - Cambò, Benedetta

AU - Beggia, Barbara

AU - Quinto, Angela Maria

AU - Pagano, Livio

AU - Sanna, Marco

AU - Del Principe, Maria Ilaria

AU - Marchesi, Francesco

AU - Fanci, Rosa

AU - Potenza, Leonardo

AU - Nosari, Annamaria

AU - Cattaneo, Chiara

AU - Cesaro, Simone

AU - Russo, Domenico

PY - 2017

Y1 - 2017

N2 - Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.

AB - Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections. Although neutropenia is common to almost all hematologic patients, other factors play a key role in specific patients, in particular in patients with AML or allogeneic HSCT recipients. Defining those patients at higher risk of IFIs may help to design the most appropriate diagnostic work-up and antifungal strategy.

UR - http://hdl.handle.net/10447/238022

M3 - Article

VL - 31

SP - 17

EP - 29

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

ER -